$1.40
6.04% today
Nasdaq, Apr 04, 10:10 pm CET
ISIN
US00461U1051
Symbol
ACRS
Sector
Industry

Aclaris Therapeutics, Inc. Stock price

$1.40
-0.53 27.46% 1M
+0.21 17.65% 6M
-1.08 43.55% YTD
+0.17 13.82% 1Y
-15.68 91.80% 3Y
+0.25 21.74% 5Y
-9.65 87.33% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
-0.09 6.04%
ISIN
US00461U1051
Symbol
ACRS
Sector
Industry

Key metrics

Market capitalization $160.80m
Enterprise Value $49.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.66
P/S ratio (TTM) P/S ratio 8.59
P/B ratio (TTM) P/B ratio 1.03
Revenue growth (TTM) Revenue growth -40.09%
Revenue (TTM) Revenue $18.72m
EBIT (operating result TTM) EBIT $-49.90m
Free Cash Flow (TTM) Free Cash Flow $-20.20m
Cash position $113.59m
EPS (TTM) EPS $-1.51
P/E forward negative
P/S forward 9.35
EV/Sales forward 2.90
Short interest 6.68%
Show more

Is Aclaris Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Aclaris Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Aclaris Therapeutics, Inc. forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Aclaris Therapeutics, Inc. forecast:

Buy
83%
Hold
17%

Financial data from Aclaris Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
19 19
40% 40%
100%
- Direct Costs 15 15
69% 69%
83%
3.26 3.26
85% 85%
17%
- Selling and Administrative Expenses 19 19
34% 34%
100%
- Research and Development Expense 34 34
66% 66%
179%
-49 -49
53% 53%
-262%
- Depreciation and Amortization 0.79 0.79
8% 8%
4%
EBIT (Operating Income) EBIT -50 -50
53% 53%
-267%
Net Profit -132 -132
49% 49%
-706%

In millions USD.

Don't miss a Thing! We will send you all news about Aclaris Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aclaris Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about one month ago
WAYNE, Pa., March 04, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in two upcoming healthcare conferences in March. On Tuesday March 11, 2025, at 3:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal...
Neutral
GlobeNewsWire
about 2 months ago
- Data Generated to Date Support Potential for Aclaris' ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the availability of a new publication describing the un...
Neutral
GlobeNewsWire
2 months ago
WAYNE, Pa., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board (SAB), which initially includes experts in the field of pulmonology. These include Marianne Mann, M.D.
More Aclaris Therapeutics, Inc. News

Company Profile

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.

Head office United States
CEO Neal Walker
Employees 64
Founded 2012
Website www.aclaristx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today